{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T10:19:28Z","timestamp":1788430768541,"version":"build-2803163510"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:00:00Z","timestamp":1785801600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:00:00Z","timestamp":1785801600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100008678","name":"Universit\u00e4t Leipzig","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100008678","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Tauopathies are neurodegenerative disorders characterized by accumulating misfolded, insoluble tau protein aggregates in neurons or glial cells. In this study, we screened the\n                    <jats:italic>Spectrum Collection<\/jats:italic>\n                    and other compound libraries for inhibitors of tau self-interaction using a structural complementation reporter system (\n                    <jats:italic>NanoLuciferase Binary Technology<\/jats:italic>\n                    ). Resulting candidates were tested in dose-response assays and evaluated for cell toxicity and microtubule destabilization. Further, a seed-induced tau interaction biosensor assay and a cell-free tau Real-Time Quaking-Induced Conversion assay have been established to study their effects on the kinetics of tau interaction and aggregation, respectively. The substances ritanserin, 3-methoxycatechol, gambogic amide, azaoxafluorenes VT11, and NS 185 and thieno[2,3-d][1.3]oxazine B6\/55 showed a concentration-dependent tau self-interaction inhibition without relevant cell toxicity or microtubule destabilization. Ritanserin, VT11, NS 185 and B6\/55 blocked tau interaction in the seed-induced tau interaction biosensor assay. Finally, the cell-free tau RT-QuIC assay displayed highest inhibitory potential for VT11. Thus, the azaoxafluorene VT11 seems to be a promising candidate for further investigations as tau interaction inhibitor to address a pivotal pathological process in Alzheimer\u2019s disease and other tauopathies.\n                  <\/jats:p>","DOI":"10.1038\/s41598-026-65368-w","type":"journal-article","created":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T07:46:56Z","timestamp":1785829616000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["NanoBiT screening identifies the azaoxafluorene VT11 as potent tau interaction inhibitor"],"prefix":"10.1038","volume":"16","author":[{"given":"Niya","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Stieler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Hilbrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Vogel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Hilgeroth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Detlef","family":"Briel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Schaefer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max","family":"Holzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8670-6148","authenticated-orcid":false,"given":"Moritz","family":"Metelmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,4]]},"reference":[{"key":"65368_CR1","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/j.tips.2017.03.011","volume":"38","author":"ME Orr","year":"2017","unstructured":"Orr, M. E., Sullivan, A. C. & Frost, B. A Brief Overview of Tauopathy: Causes, Consequences, and Therapeutic Strategies. Trends Pharmacol. Sci. 38, 637\u2013648. https:\/\/doi.org\/10.1016\/j.tips.2017.03.011 (2017).","journal-title":"Trends Pharmacol. Sci."},{"key":"65368_CR2","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/nature23002","volume":"547","author":"AWP Fitzpatrick","year":"2017","unstructured":"Fitzpatrick, A. W. P. et al. Cryo-EM structures of tau filaments from Alzheimer\u2019s disease. Nature 547, 185\u2013190. https:\/\/doi.org\/10.1038\/nature23002 (2017).","journal-title":"Nature"},{"key":"65368_CR3","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s13024-022-00533-z","volume":"17","author":"Y Zhang","year":"2022","unstructured":"Zhang, Y. et al. Tauopathies: new perspectives and challenges. Mol. Neurodegener. 17, 28. https:\/\/doi.org\/10.1186\/s13024-022-00533-z (2022).","journal-title":"Mol. Neurodegener"},{"key":"65368_CR4","doi-asserted-by":"publisher","first-page":"2633","DOI":"10.4103\/1673-5374.373670","volume":"18","author":"M Robbins","year":"2023","unstructured":"Robbins, M. Therapies for Tau-associated neurodegenerative disorders: targeting molecules, synapses, and cells. Neural Regen Res. 18, 2633\u20132637. https:\/\/doi.org\/10.4103\/1673-5374.373670 (2023).","journal-title":"Neural Regen Res."},{"key":"65368_CR5","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1152\/physrev.00024.2003","volume":"84","author":"J Avila","year":"2004","unstructured":"Avila, J. et al. Role of tau protein in both physiological and pathological conditions. Physiol. Rev. 84, 361\u2013384. https:\/\/doi.org\/10.1152\/physrev.00024.2003 (2004).","journal-title":"Physiol. Rev."},{"key":"65368_CR6","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1038\/nrn2194","volume":"8","author":"C Ballatore","year":"2007","unstructured":"Ballatore, C., Lee, V. M. Y. & Trojanowski, J. Q. Tau-mediated neurodegeneration in Alzheimer\u2019s disease and related disorders. Nat. Rev. Neurosci. 8, 663\u2013672. https:\/\/doi.org\/10.1038\/nrn2194 (2007).","journal-title":"Nat. Rev. Neurosci."},{"key":"65368_CR7","doi-asserted-by":"publisher","first-page":"13806","DOI":"10.1074\/jbc.M800247200","volume":"283","author":"EE Congdon","year":"2008","unstructured":"Congdon, E. E. et al. Nucleation-dependent Tau Filament Formation. J. Biol. Chem. 283, 13806\u201313816. https:\/\/doi.org\/10.1074\/jbc.M800247200 (2008).","journal-title":"J. Biol. Chem."},{"key":"65368_CR8","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1111\/jnc.13866","volume":"139","author":"S Wegmann","year":"2016","unstructured":"Wegmann, S. et al. Formation, release, and internalization of stable tau oligomers in cells. J. Neurochem. 139, 1163\u20131174. https:\/\/doi.org\/10.1111\/jnc.13866 (2016).","journal-title":"J. Neurochem"},{"key":"65368_CR9","doi-asserted-by":"publisher","unstructured":"Holzer, M. et al. Novel Protein Kinase Inhibitors Related to Tau Pathology Modulate Tau Protein-Self Interaction Using a Luciferase Complementation Assay. Molecules 23 https:\/\/doi.org\/10.3390\/molecules23092335 (2018).","DOI":"10.3390\/molecules23092335"},{"key":"65368_CR10","doi-asserted-by":"publisher","first-page":"2248","DOI":"10.1038\/s41598-018-20565-0","volume":"8","author":"M Oberstadt","year":"2018","unstructured":"Oberstadt, M. et al. TDP-43 self-interaction is modulated by redox-active compounds Auranofin, Chelerythrine and Riluzole. Sci. Rep. 8, 2248. https:\/\/doi.org\/10.1038\/s41598-018-20565-0 (2018).","journal-title":"Sci. Rep."},{"key":"65368_CR11","doi-asserted-by":"publisher","first-page":"e8071","DOI":"10.15252\/msb.20178071","volume":"14","author":"P Trepte","year":"2018","unstructured":"Trepte, P. et al. LuTHy: a double-readout bioluminescence-based two-hybrid technology for quantitative mapping of protein-protein interactions in mammalian cells. Mol. Syst. Biol. 14, e8071. https:\/\/doi.org\/10.15252\/msb.20178071 (2018).","journal-title":"Mol. Syst. Biol."},{"key":"65368_CR12","doi-asserted-by":"publisher","first-page":"543","DOI":"10.3389\/fphar.2020.00543","volume":"11","author":"S Ramirez-Rios","year":"2020","unstructured":"Ramirez-Rios, S. et al. A New Quantitative Cell-Based Assay Reveals Unexpected Microtubule Stabilizing Activity of Certain Kinase Inhibitors, Clinically Approved or in the Process of Approval. Front. Pharmacol. 11, 543. https:\/\/doi.org\/10.3389\/fphar.2020.00543 (2020).","journal-title":"Front. Pharmacol."},{"key":"65368_CR13","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/78078","volume":"25","author":"J Lewis","year":"2000","unstructured":"Lewis, J. et al. Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein. Nat. Genet. 25, 402\u2013405. https:\/\/doi.org\/10.1038\/78078 (2000).","journal-title":"Nat. Genet."},{"key":"65368_CR14","doi-asserted-by":"publisher","first-page":"3889","DOI":"10.1111\/ejn.14923","volume":"53","author":"S Schmidt","year":"2021","unstructured":"Schmidt, S. et al. Aggrecan modulates the expression and phosphorylation of tau in a novel bigenic TauP301L - Acan mouse model. Eur. J. Neurosci. 53, 3889\u20133904. https:\/\/doi.org\/10.1111\/ejn.14923 (2021).","journal-title":"Eur. J. Neurosci."},{"key":"65368_CR15","doi-asserted-by":"publisher","unstructured":"Schmidt, S. et al. Tau Protein Modulates Perineuronal Extracellular Matrix Expression in the TauP301L-acan Mouse Model. Biomolecules 12 https:\/\/doi.org\/10.3390\/biom12040505 (2022).","DOI":"10.3390\/biom12040505"},{"key":"65368_CR16","doi-asserted-by":"publisher","first-page":"4506","DOI":"10.1073\/pnas.85.12.4506","volume":"85","author":"CM Wischik","year":"1988","unstructured":"Wischik, C. M. et al. Isolation of a fragment of tau derived from the core of the paired helical filament of Alzheimer disease. Proc. Natl. Acad. Sci. U S A. 85, 4506\u20134510. https:\/\/doi.org\/10.1073\/pnas.85.12.4506 (1988).","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"65368_CR17","doi-asserted-by":"publisher","first-page":"12535","DOI":"10.1038\/s41598-021-91856-2","volume":"11","author":"R Rozbeh","year":"2021","unstructured":"Rozbeh, R. & Forchhammer, K. Split NanoLuc technology allows quantitation of interactions between PII protein and its receptors with unprecedented sensitivity and reveals transient interactions. Sci. Rep. 11, 12535. https:\/\/doi.org\/10.1038\/s41598-021-91856-2 (2021).","journal-title":"Sci. Rep."},{"key":"65368_CR18","doi-asserted-by":"publisher","first-page":"6914","DOI":"10.1016\/j.bmcl.2012.09.006","volume":"22","author":"V Tell","year":"2012","unstructured":"Tell, V. et al. Multitargeted drug development: Discovery and profiling of dihydroxy substituted 1-aza-9-oxafluorenes as lead compounds targeting Alzheimer disease relevant kinases. Bioorg. Med. Chem. Lett. 22, 6914\u20136918. https:\/\/doi.org\/10.1016\/j.bmcl.2012.09.006 (2012).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"65368_CR19","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.4155\/fmc-2022-0061","volume":"14","author":"A Opitz","year":"2022","unstructured":"Opitz, A. et al. Novel effective small-molecule inhibitors of protein kinases related to tau pathology in Alzheimer\u2019s disease. Future Med. Chem. 14, 1175\u20131186. https:\/\/doi.org\/10.4155\/fmc-2022-0061 (2022).","journal-title":"Future Med. Chem."},{"key":"65368_CR20","doi-asserted-by":"publisher","first-page":"4704","DOI":"10.2174\/092986709789878283","volume":"16","author":"D Briel","year":"2009","unstructured":"Briel, D. et al. Synthesis of thieno2,3-doxazines and thieno2,3-dthiazines as subtype specific kainate receptor antagonists. Curr. Med. Chem. 16, 4704\u20134711. https:\/\/doi.org\/10.2174\/092986709789878283 (2009).","journal-title":"Curr. Med. Chem."},{"key":"65368_CR21","doi-asserted-by":"publisher","first-page":"9072","DOI":"10.1002\/chem.201500556","volume":"21","author":"T Klingstedt","year":"2015","unstructured":"Klingstedt, T. et al. Distinct Spacing Between Anionic Groups: An Essential Chemical Determinant for Achieving Thiophene-Based Ligands to Distinguish \u03b2-Amyloid or Tau Polymorphic Aggregates. Chemistry 21, 9072\u20139082. https:\/\/doi.org\/10.1002\/chem.201500556 (2015).","journal-title":"Chemistry"},{"key":"65368_CR22","doi-asserted-by":"publisher","first-page":"3348","DOI":"10.1002\/cbic.202100383","volume":"22","author":"M Ramesh","year":"2021","unstructured":"Ramesh, M. et al. Thiophene-Based Dual Modulators of A\u03b2 and Tau Aggregation. Chembiochem 22, 3348\u20133357. https:\/\/doi.org\/10.1002\/cbic.202100383 (2021).","journal-title":"Chembiochem"},{"key":"65368_CR23","doi-asserted-by":"publisher","first-page":"12827","DOI":"10.1038\/s41598-020-69744-y","volume":"10","author":"A Dominguez-Meijide","year":"2020","unstructured":"Dominguez-Meijide, A. et al. Effects of pharmacological modulators of \u03b1-synuclein and tau aggregation and internalization. Sci. Rep. 10, 12827. https:\/\/doi.org\/10.1038\/s41598-020-69744-y (2020).","journal-title":"Sci. Rep."},{"key":"65368_CR24","doi-asserted-by":"publisher","unstructured":"L\u00f6vestam, S. et al. Assembly of recombinant tau into filaments identical to those of Alzheimer\u2019s disease and chronic traumatic encephalopathy. Elife 11. (2022). https:\/\/doi.org\/10.7554\/eLife.76494","DOI":"10.7554\/eLife.76494"},{"key":"65368_CR25","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1002\/1873-3468.13675","volume":"594","author":"YK Al-Hilaly","year":"2020","unstructured":"Al-Hilaly, Y. K. et al. Tau (297\u2013391) forms filaments that structurally mimic the core of paired helical filaments in Alzheimer\u2019s disease brain. FEBS Lett. 594, 944\u2013950. https:\/\/doi.org\/10.1002\/1873-3468.13675 (2020).","journal-title":"FEBS Lett."},{"key":"65368_CR26","doi-asserted-by":"publisher","unstructured":"Cecon, E. et al. Novel repertoire of tau biosensors to monitor pathological tau transformation and seeding activity in living cells. Elife 12 https:\/\/doi.org\/10.7554\/eLife.78360 (2023).","DOI":"10.7554\/eLife.78360"},{"key":"65368_CR27","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1007\/s00401-013-1114-9","volume":"125","author":"J Wagner","year":"2013","unstructured":"Wagner, J. et al. Anle138b: a novel oligomer modulator for disease-modifying therapy of neurodegenerative diseases such as prion and Parkinson\u2019s disease. Acta Neuropathol. 125, 795\u2013813. https:\/\/doi.org\/10.1007\/s00401-013-1114-9 (2013).","journal-title":"Acta Neuropathol."},{"key":"65368_CR28","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1007\/s00401-017-1692-z","volume":"133","author":"E Saijo","year":"2017","unstructured":"Saijo, E. et al. Ultrasensitive and selective detection of 3-repeat tau seeding activity in Pick disease brain and cerebrospinal fluid. Acta Neuropathol. 133, 751\u2013765. https:\/\/doi.org\/10.1007\/s00401-017-1692-z (2017).","journal-title":"Acta Neuropathol."},{"key":"65368_CR29","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s40478-020-0887-z","volume":"8","author":"MA Metrick","year":"2020","unstructured":"Metrick, M. A. et al. A single ultrasensitive assay for detection and discrimination of tau aggregates of Alzheimer and Pick diseases. Acta Neuropathol. Commun. 8, 22. https:\/\/doi.org\/10.1186\/s40478-020-0887-z (2020).","journal-title":"Acta Neuropathol. Commun."},{"key":"65368_CR30","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1097\/WNR.0000000000000930","volume":"29","author":"K Mizutani","year":"2018","unstructured":"Mizutani, K., Sonoda, S. & Wakita, H. Ritanserin, a serotonin-2 receptor antagonist, inhibits functional recovery after cerebral infarction. Neuroreport 29, 54\u201358. https:\/\/doi.org\/10.1097\/WNR.0000000000000930 (2018).","journal-title":"Neuroreport"},{"key":"65368_CR31","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.jchemneu.2019.01.008","volume":"96","author":"S Afshar","year":"2019","unstructured":"Afshar, S. et al. Protective effects of 5-HT1A receptor antagonist and 5-HT2A receptor agonist on the biochemical and histological features in a rat model of Alzheimer\u2019s disease. J. Chem. Neuroanat. 96, 140\u2013147. https:\/\/doi.org\/10.1016\/j.jchemneu.2019.01.008 (2019).","journal-title":"J. Chem. Neuroanat."},{"key":"65368_CR32","doi-asserted-by":"publisher","first-page":"5482","DOI":"10.1002\/alz.13090","volume":"19","author":"K Jahreis","year":"2023","unstructured":"Jahreis, K. et al. Amisulpride as a potential disease-modifying drug in the treatment of tauopathies. Alzheimers Dement. 19, 5482\u20135497. https:\/\/doi.org\/10.1002\/alz.13090 (2023).","journal-title":"Alzheimers Dement."},{"key":"65368_CR33","doi-asserted-by":"publisher","unstructured":"Sayas, C. L. & \u00c1vila, J. GSK-3 and Tau: A Key Duet in Alzheimer\u2019s Disease. Cells 10. (2021). https:\/\/doi.org\/10.3390\/cells10040721","DOI":"10.3390\/cells10040721"},{"key":"65368_CR34","doi-asserted-by":"publisher","first-page":"e14382","DOI":"10.1371\/journal.pone.0014382","volume":"5","author":"A Fiorentini","year":"2010","unstructured":"Fiorentini, A. et al. Lithium improves hippocampal neurogenesis, neuropathology and cognitive functions in APP mutant mice. PLoS ONE. 5, e14382. https:\/\/doi.org\/10.1371\/journal.pone.0014382 (2010).","journal-title":"PLoS ONE"},{"key":"65368_CR35","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1172\/JCI64516","volume":"123","author":"PTT Ly","year":"2013","unstructured":"Ly, P. T. T. et al. Inhibition of GSK3\u03b2-mediated BACE1 expression reduces Alzheimer-associated phenotypes. J. Clin. Invest. 123, 224\u2013235. https:\/\/doi.org\/10.1172\/JCI64516 (2013).","journal-title":"J. Clin. Invest."},{"key":"65368_CR36","doi-asserted-by":"publisher","first-page":"102058","DOI":"10.1016\/j.isci.2021.102058","volume":"24","author":"AC Amaral","year":"2021","unstructured":"Amaral, A. C. et al. Isoform-selective decrease of glycogen synthase kinase-3-beta (GSK-3\u03b2) reduces synaptic tau phosphorylation, transcellular spreading, and aggregation. iScience 24, 102058. https:\/\/doi.org\/10.1016\/j.isci.2021.102058 (2021).","journal-title":"iScience"},{"key":"65368_CR37","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1016\/S0026-895X(25)12558-3","volume":"27","author":"JE Leysen","year":"1985","unstructured":"Leysen, J. E. et al. Receptor-binding properties in vitro and in vivo of ritanserin: A very potent and long acting serotonin-S2 antagonist. Mol. Pharmacol. 27, 600\u2013611 (1985).","journal-title":"Mol. Pharmacol."},{"key":"65368_CR38","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.pharep.2014.09.002","volume":"67","author":"J Shen","year":"2015","unstructured":"Shen, J. & Yu, Q. Gambogic amide selectively upregulates TrkA expression and triggers its activation. Pharmacol. Rep. 67, 217\u2013223. https:\/\/doi.org\/10.1016\/j.pharep.2014.09.002 (2015).","journal-title":"Pharmacol. Rep."},{"key":"65368_CR39","doi-asserted-by":"publisher","first-page":"500","DOI":"10.3390\/ph6040500","volume":"6","author":"H Deng","year":"2013","unstructured":"Deng, H. & Fang, Y. The Three Catecholics Benserazide, Catechol and Pyrogallol are GPR35 Agonists. Pharmaceuticals (Basel). 6, 500\u2013509. https:\/\/doi.org\/10.3390\/ph6040500 (2013).","journal-title":"Pharmaceuticals (Basel)"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-65368-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-65368-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-65368-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T09:55:51Z","timestamp":1788429351000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-65368-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,4]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["65368"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-65368-w","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,4]]},"assertion":[{"value":"25 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"24013"}}